8-K current report · filed Jul 30, 2026

MERIT MEDICAL SYSTEMS INC (MMSI) 8-K Current Report: July 30, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.1#2MMSI overview

Short answer

MERIT MEDICAL SYSTEMS INC (MMSI) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.1#2 (Exhibit EX-99.1). Press release announces Merit Medical’s operating and financial results for quarter ended June 30, 2026.

MERIT MEDICAL SYSTEMS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Merit Medical’s operating and financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed earnings release for investor review

Item 7.01 · Regulation FD Disclosure

  • Q2 2026 results conference call scheduled for July 30, covering the quarter ended June 30, 2026
  • Earnings press release and presentation furnished as Exhibits 99.1 and 99.2
  • Non-GAAP results included alongside GAAP metrics, with historical reconciliations
  • No GAAP guidance beyond revenue, limiting comparability with adjusted outlook measures
  • Unpredictable acquisition, amortization, severance, litigation and regulatory costs may materially affect GAAP results

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $418.8M, up 10%; organic constant-currency growth 9%, signaling broad-based demand acceleration
  • Non-GAAP operating margin 22.6% vs 21.2%; GAAP EPS $0.65, up 20%, demonstrating strong operating leverage
  • Therapeutic revenue up 15%, led by Endoscopy up 29% and Cardiac Therapies up 24%; Procedural Solutions declined 12%
  • 2026 guidance raised to revenue $1.631–$1.643B and non-GAAP EPS $4.25–$4.35
  • Year-to-date operating cash flow $110.0M, down 11%; debt $747.5M versus cash $448.7M, limiting balance-sheet flexibility despite approximately $697M borrowing capacity

Item EX-99.1#2 · Exhibit EX-99.1

  • Q2 revenue $418.8M, up 9.5%, with domestic growth 11.0% and international growth 7.3%
  • GAAP operating margin 14.4% versus 12.3%, while EPS rose 20.3% to $0.65
  • Organic constant-currency revenue increased 9.0%, indicating growth beyond acquired businesses and currency effects
  • 2026 guidance raised: revenue $1.631-$1.643B and non-GAAP EPS $4.25-$4.35
  • Operating cash flow fell to $69.3M from $83.3M, warranting attention despite stronger earnings growth

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MERIT MEDICAL SYSTEMS INC 8-K filings

Get the next MMSI 8-K as it lands

Follow MMSI for push alerts, or ask the research agent what this filing means.